Coreceptors and HIV-1 pathogenesis

被引：100

作者：

Gorry P.R. ^{[1
,2
]}

Ancuta P. ^{[3
,4
,5
]}

机构：

[1] Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC

[2] Department of Medicine, Monash University, Melbourne, VIC

[3] Department of Microbiology and Immunology, Université de Montréal, Montreal, QC

[4] CHUM-Research Center, Saint-Luc Hospital, Montreal, QC

[5] French National Institute of Health and Medical Research, Montreal, QC

来源：

Current HIV/AIDS Reports | 2011年 / 8卷 / 1期

关键词：

CCR5; CD4+ T cells; Coreceptors; CXCR4; Dendritic cells; HIV-1; Macrophages; Monocytes; Pathogenesis; Reservoirs; Tropism;

D O I：

10.1007/s11904-010-0069-x

中图分类号：

学科分类号：

摘要：

The major HIV-1 coreceptors, CCR5 and CXCR4, mediate virus entry into CD4+ cells and are therefore a critical component of the HIV-1 life cycle. Alterations in coreceptor preference as well as the efficiency and mechanism of interaction between HIV-1 and CCR5 and/or CXCR4 has a significant influence on viral tropism, progression of disease, and response to coreceptor antagonists. In addition, these alterations influence the susceptibility of CD4+ T-cell, monocyte, and dendritic cell subsets to infection and therefore, are important for several facets of HIV-1 pathogenesis including the establishment of latent reservoirs, trafficking, and transmission. This review highlights recent literature that has advanced our understanding of the role of coreceptors in HIV-1 pathogenesis. © 2010 Springer Science+Business Media, LLC.

引用

页码：45 / 53

页数：8

共 50 条

[21]

Loftin L.M., Kienzle M.F., Yi Y., Lee B., Lee F.H., Gray L., Gorry P.R., Collman R.G., Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: Efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry, Virology, 402, pp. 135-148, (2010)

[22]

Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., Perros M., Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry, J Virol, 81, pp. 2359-2371, (2007)

[23]

Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E., HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry, Virology, 361, pp. 212-228, (2007)

[24]

Tilton J.C., Amrine-Madsen H., Miamidian J.L., Kitrinos K.M., Pfaff J., Demarest J.F., Ray N., Jeffrey J.L., Labranche C.C., Doms R.W., HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry, AIDS Res Hum Retroviruses, 26, pp. 13-24, (2010)

[25]

Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., Henning E.A., Bushman F.D., Martin J.N., Deeks S.G., Doms R.W., A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5, J Virol, 84, pp. 10863-10876, (2010)

[26]

Berro R., Sanders R.W., Lu M., Klasse P.J., Moore J.P., Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry, PLoS Pathog, 5, (2009)

[27]

Anastassopoulou C.G., Ketas T.J., Klasse P.J., Moore J.P., Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41, Proc Natl Acad Sci USA, 106, pp. 5318-5323, (2009)

[28]

Pugach P., Ray N., Klasse P.J., Ketas T.J., Michael E., Doms R.W., Lee B., Moore J.P., Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities, Virology, 387, pp. 296-302, (2009)

[29]

Anastassopoulou C.G., Marozsan A.J., Matet A., Snyder A.D., Arts E.J., Kuhmann S.E., Moore J.P., Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss, PLoS Pathog, 3, (2007)

[30]

Douek D.C., Roederer M., Koup R.A., Emerging concepts in the immunopathogenesis of AIDS, Annu Rev Med, 60, pp. 471-484, (2009)

← 1 2 3 4 5 →